

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: FinCanna Capital Corp. (the "Issuer").

Trading Symbol: CALI

Number of Outstanding Listed Securities: 98,289,734

Date: September 6, 2018

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

FinCanna Capital Corp. ("FinCanna") is a royalty company for the licensed medical cannabis industry which invests in sizable and scalable best-in-class businesses. Over the past month, FinCanna has continued to work towards achieving its business objective of providing capital solutions to companies in the medical cannabis industry with large scale

potential and a highly skilled and experienced operator, which plan to produce high value, high demand licensed medical products or related products and services.

On August 8, 2018, FinCanna announced that it had advanced US\$ 1 million to its investee company ezGreen Compliance, which offers state-of-the-art enterprise compliance and point-of-sale software solutions for licensed medical cannabis dispensaries and cultivators.

FinCanna reported that ezGreen will be allocating the capital to advance their comprehensive compliance strategy which will include the expansion of their sales department and the hiring of a project management team to support the company's marketing effort to their affiliate network which includes a pipeline of over 200 dispensary client locations.

Additionally, the company aims to accelerate the technological development of their Cannabis-National Drug Code (NDC) program, which includes multiple integrations with leading cannabis technology platforms. ezGreen will also be investing to further advance their all-inclusive suite of products and services which provides their dispensary customers with a front-to-back compliance solution including secure customer data storage and transmission, Health Insurance Portability and Accountability Act (HIPAA) certified reporting and third-party inventory validation. The ezGreen technologies are designed to work with all existing client hardware in delivering a seamless and cost-effective transition to their fully compliant management and reporting system.

On August 13, 2018, FinCanna announced that it had advanced US \$1.25 million, the initial tranche of capital, to its investee company Refined Resin Technologies Inc. ("Refined Resin") of Oakland, California.

This was the first of a series of tranches of capital that will be advanced to Refined Resin over the next few months as key milestones are accomplished in accordance with the terms of the Royalty Agreement previously announced. FinCanna, with its recently completed financing of C\$6.8 million, is currently fully funded to make the additional payments when certain milestones are met.

Royalty payments to FinCanna from Refined Resin are equal to 11.75% on the first US\$160 million of annual revenues payable in perpetuity subject to certain buy-back options.

The capital will be applied to the implementation of Refined Resin's three-phase development strategy leading to commercial launch of its operation. Refined Resin is a cannabinoid research and refinery company that provides B2B and B2C products and services to licensed dispensaries and distributors in the medical cannabis supply chain. The company's intention is to become a premier producer of bulk quantities of THC distillate and various high value concentrates produced via hydrocarbon-based solvent extraction.

August 22, 2018, FinCanna announced that it had advanced US\$1 million, the second tranche of capital, to its investee company Refined Resin. This capital was the second in a series of tranches to be advanced as Refined Resin implements its three-phase

development strategy to operationalize its legally zoned, large, state-of-the-art medical cannabis extraction laboratory.

With this second tranche of funding completed, Refined Resin has now placed deposits and has funds in reserve to complete the purchase of all equipment required to commence production once installed. Sourced from three premier national suppliers, substantial aspects of the specialized production equipment are custom designed to facilitate Refined Resin's high volume, low cost approach to production. The extraction facility is targeted to be in commercial operation by late 2018 or early 2019.

On August 30, 2018, FinCanna announced the appointment of Mr. Robert Kamm to its Board of Directors.

Mr. Kamm has over 25 years of experience operating and advising businesses from large Fortune 500 corporations to venture capital backed companies and has served on Boards of Directors of both public and private companies during this time period. He also formerly held the position of Vice President of Union Bank, Los Angeles. Mr. Kamm currently represents FinCanna on the Board of Directors of Cultivation Technologies Inc., a FinCanna investee company.

Mr. Kamm is currently a principle and the Entrepreneur in Residence at Sandy Hill Venture Capital. Founded in 2007, Sandy Hill is a San Francisco Bay area firm that invests in and advises emerging business in the Clean Tech, Fintech, Healthcare, Internet Security, and Software industries. Mr. Kamm is an active participant in the Bay Area investment community and is an original and active member of the Keiretsu Forum. Founded in 2007 the Keiretsu Forum is a global investment community of over 2,500 accredited private equity angel investors, venture capitalists and corporate/institutional investors. It is one of the largest angel investment organizations globally with 52 chapters on 3 continents, whose members to date have invested over \$800 million dollars in over 800 companies.

Mr. Kamm is also an active member of Pitchforce, a San Francisco based forum that assists young entrepreneurs seeking venture capital. Mr. Kamm holds a Masters of Business Administration degree in finance and strategy from UCLA.

Mr. Jeff Tindale has resigned from the FinCanna Board of Directors making way for Mr. Kamm's appointment. Mr. Tindale will continue to act on FinCanna's Board of Advisors.

The Company also announced that on August 29, 2018, FinCanna issued a total of 450,000 incentive stock options to a director and an advisor with an exercise price of \$0.30 per share and a term of five years.

2. Provide a general overview and discussion of the activities of management.
The Company remains focused on sourcing and funding top-tier companies operating in the licensed medical cannabis sector for royalties.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or

production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None to report during the month of August, 2018.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report during the month of August, 2018.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None to report during the month of August, 2018.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report during the month of August, 2018.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report during the month of August, 2018.

8. Describe the acquisition of new customers or loss of customers.

None to report during the month of August, 2018.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None to report during the month of August, 2018.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None to report during the month of August, 2018.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report during the month of August, 2018.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal

parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report during the month of August, 2018.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None to report during the month of August, 2018.

14. Provide details of any securities issued and options or warrants granted.

| Security | Number Issued | Details of Issuance | Use of Proceeds⁽¹⁾ |
|-----------------|----------------------|---|--------------------------------------|
| Stock Options | 450,000 | Incentive stock options issued to a director and advisor with an exercise price of \$0.30 per share for a term of five years. | N/A |

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None to report during the month of August, 2018.

16. Provide details of any changes in directors, officers or committee members.

None to report during the month of August, 2018.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None to report during the month of August, 2018.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated September 6, 2018.

Jeff Dare
Name of Director or Senior
Officer

"Jeff Dare"
Signature

Corporate Secretary
Official Capacity

| | | |
|--|---|--|
| Issuer Details Name of Issuer | For Month End | Date of Report YY/MM/D |
| FinCanna Capital Corp. | August, 2018 | 18/09/06 |
| Issuer Address Suite 550 – 800 West Pender Street | | |
| City/Province/Postal Code Vancouver, BC V6C 2V6 | Issuer Fax No. (778) 327 6675 | Issuer Telephone No. (778) 327 5799 |
| Contact Name Jeff Dare | Contact Position Corporate Secretary | Contact Telephone No. (778) 327 5799 |
| Contact Email Address info@fincannacapital.com | Web Site Address www.fincannacapital.com | |